Author + information
- Sanjay Patel, MBBS, PhDa,b,
- Mahesh V. Madhavan, MDc,d,
- Roberto Spina, MBBS, MSc, MPHe,
- Gemma A. Figtree, MBBS, DPhilb,f and
- Keyvan Karimi Galougahi, MD, PhDa,b,∗ ()
- aFrom the Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
- bSydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
- cColumbia University Irving Medical Center/New York Presbyterian Hospital, New York, New York
- dCardiovascular Research Foundation, New York, New York
- eGosford Hospital, Gosford, New South Wales, Australia
- fRoyal North Shore Hospital, Sydney, New South Wales, Australia
- ↵∗Address for correspondence:
Dr. Keyvan Karimi Galougahi, Department of Cardiology, Royal Prince Alfred Hospital, 75 Missenden Road, Camperdown, Sydney, NSW 2050, Australia.
Moderate/severe calcification, present in approximately one-third of culprit lesions in acute coronary syndromes (ACS), portends unfavorable procedural and post-primary percutaneous coronary intervention outcomes. Intravascular lithotripsy is a novel technique using shockwaves to fracture calcific plaques. Presenting a clinical case, we enumerate efficacy and safety parameters in using intravascular lithotripsy in ACS. (Level of Difficulty: Advanced.)
- acute coronary syndromes
- intravascular lithotripsy
- percutaneous coronary intervention
- plaque calcification
Dr. Patel has received educational grants from Abbott Vascular and Novartis; and consultancy fees from Abbott Vascular, Novartis, and Aspen. Dr. Madhavan has received an institutional grant from the National Institutes of Health/National Heart, Lung, and Blood Institute to Columbia University Irving Medical Center (T32 HL007854). Dr. Figtree has received consultancy fees from Janssen and CSL. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Case Reports author instructions page.
- Received July 16, 2020.
- Accepted July 27, 2020.
- 2020 The Authors